Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
Go back to Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors| (NASDAQ: PLRX) | Delayed: 1.16 -0.02 (1.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.18 | 52 Week High | $ | |||
| Open | $1.20 | 52 Week Low | $ | |||
| Day High | $1.20 | P/E | N/A | |||
| Day Low | $1.14 | EPS | $ | |||
| Volume | 472,905 | |||||
